GlassScriptPhysician profile
Tarek Dammad
NPI 1457555641
$9,807.69
in general payments reported to CMS, 2019-2025
21 companies · $1,832 in 2025
The $1,832 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $231 · 2021: $826 · 2023: $307 · 2024: $5,900 · 2025: $1,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,368 · Food and Beverage: $1,477 · Travel and Lodging: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,367.50 |
| Food and Beverage | $1,476.98 |
| Travel and Lodging | $1,194.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Incorporated | $3,867.50 | 2024 | Melker |
| Intuitive Surgical, INC. | $1,731.71 | 2024-2025 | |
| Noah Medical Corporation | $1,545.86 | 2025 | Galaxy |
| Ethicon INC. | $989.33 | 2020-2023 | Monarch Platform |
| Pulmonx Corporation | $695.81 | 2019 | |
| Insmed, INC. | $168.23 | 2023-2025 | Arikayce |
| United Therapeutics Corporation | $162.09 | 2021-2024 | Orenitram, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $141.26 | 2021-2024 | Tezspire |
| Erbe USA INC | $125.00 | 2024 | |
| Mallinckrodt Hospital Products INC. | $62.31 | 2023-2025 | Acthar |
| Baxter Healthcare | $43.40 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Glaxosmithkline, LLC. | $43.34 | 2025 | Nucala |
| Ambu INC. | $34.09 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $33.62 | 2024 | Dupixent |
| Pfizer INC. | $30.70 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28.37 | 2024 | Keytruda |
| Advanced Respiratory, INC | $27.77 | 2020 | |
| Grifols USA, LLC | $25.58 | 2024 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $21.53 | 2024 | Purified Cortrophin Gel |
| Veran Medical Technologies, INC. | $15.31 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarek Dammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.